Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by aggregation of toxic forms of amyloid b peptide (Ab). Treatment strategies have largely been focused on inhibiting the enzymes (b-and c-secretases) that liberate Ab from the amyloid precursor protein (APP). While evidence suggests that individuals who exercise regularly are at reduced risk for AD and studies of animal models demonstrate that running can ameliorate brain Ab pathology and associated cognitive deficits, the underlying mechanisms are unknown. However, considerable evidence suggests that brain-derived neurotrophic factor (BDNF) mediates beneficial effects of exercise on neuroplasticity and cellular stress resistance. Here, we tested the hypothesis that BDNF promotes non-amyloidogenic APP processing. Using a transgenic mouse model of Alzheimer's disease and cultured human neural cells, we demonstrate that exercise and BDNF reduce production of toxic Ab peptides through a mechanism involving enhanced a-secretase processing of APP. This anti-amyloidogenic APP processing involves subcellular redistribution of a-secretase and an increase in intracellular neuroprotective APP peptides capable of binding and inhibiting b-secretase. Moreover, our results suggest that BDNF's ability to promote neurite outgrowth is primarily exerted through pathways other than APP processing. Exercise and other factors that enhance BDNF signaling may therefore have both therapeutic and prophylactic value in the battle against AD. Keywords: alpha-secretase, Alzheimer's disease, amyloid precursor protein, BDNF, exercise. J. Neurochem. (2017) 142, 286-296.
Several neurodegenerative diseases, including Huntington's, Parkinson's, and Alzheimer's diseases are marked by accumulation of self-aggregating neurotoxic proteins (Stranahan and Mattson 2010) . In Alzheimer's disease (AD), the production of aggregation-prone amyloid bpeptide (Ab) is thought to be an early event that promotes synaptic dysfunction, neuritic degeneration, and neuronal death (Mucke and Selkoe 2012) . Accordingly, major efforts have been placed on understanding mechanisms that regulate amyloidogenic proteolytic processing of the amyloid precursor protein (APP). APP is a single-pass transmembrane protein that is transported into neurites and present in relatively high amounts in plasma and endocytic membranes (Cirrito et al. 2008) . APP is cleaved by three enzymes, a-, b-, and c-secretases. Cleavage by a-secretase (ADAM10) occurs at the membrane surface within the Ab sequence to release a secreted form of APP (sAPPa), which is believed to modulate neuronal excitability and neurite outgrowth (Chow et al. 2010) . Sequential cleavages by b-secretase (BACE1) and c-secretase (presenilin-1) at the N-and C-termini of the Ab sequence liberates Ab (Ab40 and Ab42). Efforts to develop disease-modifying treatments for AD treatment have centered largely on drugs that inhibit c-or b-secretases, and removal of Ab using "immunotherapy" approaches (De and Chavez 2015; Heneka et al. 2015) . However, clinical trials using such approaches have failed. While it is known that cleavage of APP by a-secretase prevents Ab generation and that sAPPa is neuroprotective (Mattson et al. 1993; Furukawa et al. 1996; Obregon et al. 2012) , little is known of the signaling pathways that may stimulate a-secretase cleavage of APP.
Epidemiological findings suggest that regular exercise can reduce the risk of AD, and studies of mouse models of AD have demonstrated that running wheel exercise can lessen Ab accumulation and ameliorate cognitive deficits (Adlard et al. 2005; Mattson 2012 ). The underlying cellular and molecular mechanisms are unknown. Exercise enhances synaptic plasticity (synapse formation and increased functional connectivity) and can stimulate neurogenesis (generation of neurons from stem cells) in the hippocampus, a brain region critical for learning and memory that is heavily affected by Ab pathology and neuronal degeneration in AD (van Praag et al. 2014) . Moreover, exercise can protect neurons against excitotoxic and metabolic stress in experimental models of relevance to AD (Reiss et al. 2009; Lau et al. 2011; Cheng et al. 2016) . A large body of evidence suggests that brainderived neurotrophic factor (BDNF) plays major roles in adaptive responses of neuronal circuits to exercise including neurogenesis, synapse formation, learning and memory, and neuronal stress resistance (Intlekofer and Cotman 2013; Marosi and Mattson 2014) . Mature BDNF is generated by proteolytic cleavage of a longer pro-BDNF protein by a furin protease or plasmin. A polymorphism located at amino acid 66 in pro-BDNF (Val66Met), which may influence the amount of mature BDNF produced, has been associated with the risk of several major psychiatric disorders, including depression and eating disorders (Notaras et al. 2015) . Levels of mature BDNF and its high-affinity receptor TrkB are decreased in brain tissue samples of AD patients compared to age-matched control subjects (Hock et al. 2000; Ginsberg et al. 2006) . It was also reported that BDNF can affect subcellular trafficking of APP (Rohe et al. 2009 ) and that inhibition of BDNF signaling increases Ab generation (Matrone et al. 2008) . However, it is not known whether exercise and BDNF affect APP processing in a manner that would be expected to reduce Ab production and protect neurons against dysfunction and degeneration.
In this study, we show that running wheel exercise increases the levels of sAPPa and BDNF, with associated reductions in levels of Ab40 and Ab42, in the hippocampus of APP/presenilin 1 double-mutant transgenic mice. To test the possibility that BDNF mediates the effects of exercise on APP processing, we measured levels of sAPPa and Abs in cultured human neuroblastoma cells exposed directly to BDNF and found that BDNF reduces Ab peptides by enhancing a-secretase processing of APP. BDNF does not increase the expression of ADAM10 but instead causes a redistribution of ADAM10 away from the cell surface. Additional findings suggest that the ability of BDNF to induce neurite outgrowth is independent of its effects on asecretase. Taken together, these results suggest that BDNFmediated enhancement of non-amyloidogenic processing of APP may be one mechanism whereby exercise protects the brain against AD.
Methods

Animals
Male APP/PS1 double-mutant transgenic mice (2xTg AD mice; B6C3-Tg(APPswe,PS1D9)85Dbo) (Borchelt et al. 1997) were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and maintained under a 12 h light/12 h dark cycle with food and water available ad libitum. Once aged 7-9 months, mice were screened for 48 h to identify their propensity to participate in voluntary running on a running wheel. Mice were then randomly assigned to cages where they were housed individually either with access to a functional running wheel (runners) or with a locked running wheel (sedentary controls). After 3 weeks, mice were killed with an overdose of isoflurane anesthesia. The hippocampus was isolated, flash-frozen on dry ice, and subsequently kept at À80°C. All procedures were approved by the National Institute on Aging Animal Care and Use Committee and complied with NIH guidelines.
Antibodies and recombinant proteins
The following antibodies were used: anti-sAPPa 2B3 (RRID: AB_1630819; IBL, Gunma, Japan) and anti-ADAM10 (RRID: AB_626635; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The following recombinant proteins were used: human mature BDNF (Preprotech, Rocky Hill, NJ, USA) and human sAPPa (Sigma Aldrich, St. Louis, MO, USA). Note that we used mature BDNF and not pro-BDNF, and therefore the Val66Met polymorphism has no bearing on our findings.
Cell culture
The human neuroblastoma cell line, SHSY5Y (catalog #CRL-2266; American Type Culture Collection, Manassas, VA, USA), was cultured in Dulbecco's modified Eagle medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 10 lM retinoic acid (RA). After 2 days, some cultures were further supplemented with 50 ng/mL BDNF and/or 5 lM batimastat (Sigma Aldrich). Cultures were maintained for an additional 3 days before harvesting cells and media. For neurite outgrowth experiments, differentiation was achieved as previously described (Encinas et al. 2000) by sequentially treating cells with retinoic acid for 2 days followed by treatment with BDNF for 5 days in serum-free media. Cells were maintained at 37°C in a saturated humidity incubator containing 5% CO 2 .
Biochemistry
Measurement of Ab40, Ab42, and sAPPa in cell culture media, cell lysates, and mouse tissue lysates were performed using Mesoscale Discovery (MSD) immunoassays on a Quickplex SQ 120 (Mesoscale Discovery). The MSD multiplex ELISA platform is based on electrochemiluminescence enabling high sensitivity, specificity, and a wide dynamic range. Measurement of BDNF in mouse tissue lysates was performed using BDNF ELISA immunoassays (Promega, Madison, WI, USA) on a Synergy H1 multiplate reader (Biotek, Winooski, VT, USA). All experiments were performed according to the manufacturer's suggested protocol. Lysates were prepared radioimmunoprecipitation assay buffer supplemented with protease inhibitor cocktail (Sigma Aldrich) and 1 mM phenylmethylsulfonyl fluoride. Protein concentration was determined by Pierce bicinchoninic acid protein assay kit (Thermo Fisher Scientific). Western blots were performed by running lysates on 10% Bis-Tris Gels using NuPage MOPS sodium dodecyl sulfate running buffer (Thermo Fisher Scientific). Gels were then transferred onto 0.45 lm poresize nitrocellulose membranes (Thermo Fisher Scientific). Membranes were incubated with Pierce electrochemiluminescence Western Blotting substrate (Thermo Fisher Scientific) and developed onto autoradiography film. Densitometric analysis was performed using ImageJ.
Flow cytometry SHSY5Y cells were harvested, pelleted, and suspended in 5% normal goat serum (NGS) in phosphate-buffered saline (PBS) at a concentration of 2.0 9 10 7 cells/mL. Cell surface quantification of ADAM10 was performed using flow cytometry. Briefly, cells were pelleted and suspended in primary antibody solution for 30 min at 4°C followed by secondary antibody solution for 30 min at 4°C. Thereafter, cells were suspended in 500 lL of 2% NGS in PBS and passed through a 100 lm cell strainer before being analyzed on an LSRFortessa X-20 (BD Biosciences, San Jose, CA, USA). For each sample, 500 000 cells were analyzed. Data analysis was performed using FlowJo software.
Immunocytochemistry SHSY5Y cells were seeded at 25 000 cells/cm 2 in tissue culture plates (BD Biosciences) and cultured as described above. Cells were fixed for 15 min in PBS containing 4% paraformaldehyde. After washing with PBS, cells were incubated for 1 h with 5% normal goat serum in PBS. Cells were then incubated with primary antibody solution overnight at 4°C followed by secondary antibody solution for 1 h at 27°C. Cells were treated with Hoechst 33342 dye (Life Technologies, Carlsbad, CA, USA) for 5 min and washed with PBS. Images were acquired and analyzed using a fluorescence microscope system with ImageXpress software (Molecular Devices, Sunnyvale, CA, USA).
BACE1 inhibition assay
Inhibition of BACE1 was evaluated using the Sensolyte 520 bsecretase activity assay (Anaspec, CA, USA). Purified BACE1 was incubated with a fluorescence resonance energy transfer peptide containing a sequence derived from the Swedish APP mutation. As such, BACE1 has a preferential high affinity for the peptide. The peptide sequence is flanked by a HiLyte Fluorophore 488 nm and a QXL 520 nm quencher. Upon cleavage of the substrate, the 488 nm fluorophore was recovered and measured in a Synergy H1 plate reader (Biotek).
Neurite outgrowth assay SHSY5Y cells were seeded at a density of 15 000 cells/cm 2 and sequentially differentiated as described above. Cells were then stained with the Molecular Probes Neurite Outgrowth Staining kit (Thermo Fisher Scientific) according to the manufacturer's suggested protocol. Briefly, media was removed from cell culture plates and cells were fluorescently stained with both a cell viability marker and a cell membrane marker. A background suppression dye was added to aid in visualization. Fluorescence was then measured using a fluorescence plate reader (Biotek). Cell membrane measurements were normalized to cell viability.
Statistics
Unless otherwise noted, statistical significance was calculated using Student's t-test. Data values are given as mean AE SEM.
Results
Running wheel exercise reduces Ab levels and increases sAPPa levels in the hippocampus of 2xTgAD mice To test the role that exercise has on APP processing, 2xTgAD mice were housed individually with access to a running wheel for 3 weeks. These mice were compared to non-exercising control 2xTgAD mice whose running wheel was locked. Throughout the duration of the study, there was no difference in body weight between control (Fig. 1a ) and exercising mice (Fig. 1b) . There was a linear increase in the cumulative distance run by each mouse during the 3-week period ( Fig. 1c) and their average daily running speed remained stable (Fig. 1d) . As the hippocampus is particularly vulnerable to Ab pathology, we measured Ab40 and Ab42 levels in hippocampal tissue from runner mice and sedentary mice after 3 weeks. Using the highly sensitive and specific MSD multiplex ELISA system, we found that Ab40 and Ab42 levels were significantly reduced in runner mice as compared to sedentary control mice ( Fig. 1e and f ). These results demonstrate that even a relatively short 3-week period of exercise is sufficient to reduce Ab levels in 2xTgAD mice. Moreover, we measured sAPPa levels in the same hippocampal samples and found that running resulted in a significant increase in sAPPa levels (Fig. 1g) . Taken together, these results suggest that exercise shifts the processing of APP from the amyloidogenic to the nonamyloidogenic pathway.
BDNF decreases Ab levels through a mechanism involving enhanced a-secretase activity Although exercise can counteract neurodegenerative processes in animal models of AD, the underlying cellular and molecular mechanisms are unknown. One mechanism supported by data from previous studies involves up-regulation of BDNF expression (Mattson 2012; Marosi and Mattson 2014; Sleiman et al. 2016) . We found that BDNF levels were significantly elevated by approximately two-fold in hippocampi of runner compared to sedentary 2xTgAD mice ( Fig. 1h) . To test whether BDNF decreases Ab levels by modulating a-secretase activity, we used the inhibitor of asecretase, batimastat (Parvathy et al. 1998) . RA-differentiated human SHSY5Y neural cells were cultured in serumsupplemented media and subsequently treated with batimastat, BDNF, or the combination of batimastat and BDNF. Levels of Ab40, Ab42, and sAPPa secreted into the culture medium were measured. Treatment with batimastat resulted in a significant increase in the generation of Ab40 and Ab42 compared to untreated controls. Consistent with the in vivo experiments, treatment of cultured cells with BDNF led to a significant reduction in both secreted Ab40 and Ab42 compared to control cultures. Importantly, when cultured neural cells were co-treated with batimastat and BDNF, levels of Ab40 and Ab42 secreted into the medium remained significantly higher than in control cultures ( Fig. 2a and b) .
Thus, it appears that BDNF reduces Ab levels through a mechanism involving enhanced a-secretase activity. To (b), and sAPPa (c) released into the culture medium during a 3-day incubation period were measured using the Mesoscale multiplex ELISA system (n = 3 separate cultures per condition). *p < 0.05, **p < 0.01, ***p < 0.001 as determined by Student's t-test. further test this hypothesis, sAPPa levels were measured in culture media. As expected, treatment with batimastat significantly reduced sAPPa levels compared to control cultures. Conversely, BDNF treatment led to a significant increase in sAPPa levels compared to controls. In cultures co-treated with batimastat and BDNF, sAPPa levels remained significantly reduced compared to control (Fig. 2c) . Taken together, these results indicate that BDNF likely reduces Ab levels by enhancing a-secretase activity.
BDNF reduces cell surface ADAM10 levels
The increase in sAPPa levels upon BDNF treatment indicates an enhancement of a-secretase activity. To test the possibility that an increase in a-secretase expression drives this enhancement in activity, immunoblots were performed. ADAM10, the main active component of asecretase (Kuhn et al. 2010) , was assessed in RA-differentiated SHSY5Y cells treated with batimastat, BDNF, batimastat plus BDNF, or vehicle control. In each case, there was no difference in the levels of processed or active ADAM10 (Fig. 3a) . a-secretase processing is thought to primarily occur at the cell surface (Chow et al. 2010) . To test the hypothesis that BDNF increases the amount of cell surface ADAM10, cells were cultured either with or without BDNF and assessed by flow cytometry for their cell surfaceassociated ADAM10 (Fig. 3b) . To our surprise, BDNF significantly reduced the percentage of cells expressing ADAM10 on their surface when compared to control cultures (Fig. 3c) . Moreover, the amount of ADAM10 (as indicated by mean fluorescence intensity) was significantly reduced on the surface of the total cell population (Fig. 3d) .
In addition to these quantitative experiments, immunocytochemical labeling was also performed. Representative images are shown (Fig. 3e) . Taken together, these results indicate that the distribution of ADAM10 upon BDNF treatment is shifted toward intracellular accumulation. This finding is consistent with studies that suggest that regulated a-secretase activity occurs intracellularly (Skovronsky et al. 2000) .
BDNF may regulate BACE1 activity via its effect on APP processing When taken together with increased secretion of sAPPa into the culture medium, the redistribution of ADAM10 upon BDNF treatment suggests that a-secretase cleavage occurs intracellularly. Using a specific sAPPa antibody, nonsecreted sAPPa levels from cell lysates were measured by immunoblot (Fig. 4a) . Consistent with MSD measurements of sAPPa secreted in media, sAPPa levels were reduced in cell lysates from cultures treated with batimastat compared to control cultures. Notably, BDNF-treated cell cultures exhibited increased sAPPa levels in their lysates compared to control (12.5% increase; p < 0.05). Co-treatment with batimastat and BDNF resulted in reduced sAPPa levels compared to control. sAPPa levels were higher in cells cotreated with batimastat and BDNF compared to cells treated only with batimastat, although the sAPPa levels did not reach the level in cells treated with BDNF alone (Fig. 4a) . The physiological functions of secreted sAPPa are thought to include neuroprotection, neurite outgrowth, synaptogenesis, and cell adhesion. However, the function of intracellular sAPPa is poorly understood. Recent evidence suggests that sAPPa may be involved in direct inhibition of BACE1 (Obregon et al. 2012) . To confirm this possibility, an in vitro BACE1 activity assay was performed using recombinant sAPPa. Recombinant sAPPa inhibited BACE1 activity in a dose-dependent manner until a plateau was reached at a concentration of 0.5 nM (Fig. 4b) . This result indicates that sAPPa can inhibit BACE1 independently (i.e., without helper molecules or cofactors). Indeed, BDNF-treated cell cultures secreted less sAPPb into the culture media compared to control (18% decrease; p < 0.05). This finding supports the notion that BDNF may reduce amyloidogenic processing of APP through sAPPa.
BDNF promotes neurite outgrowth primarily through pathways other than APP processing Whether BDNF promotes neurite outgrowth through enhanced sAPPa production is unclear. To test this Fig. 4 Brain-derived neurotrophic factor (BDNF) treatment produces sAPPa that inhibits b-secretase (BACE1), but sAPPa does not mediate BDNF-induced neurite outgrowth. (a) Cell lysates from SHSY5Y cell cultures treated with a-secretase inhibitor (a-secr.Inh.) (5 lM batimastat), 50 ng/mL BDNF or a combination of batimastat and BDNF for 72 h were assessed by immunoblot for their cellular sAPPa levels. Actin was used as a loading control. A representative blot is shown (n = 3 separate cultures). (b) A fluorescence resonance energy transfer (FRET)-based BACE1 activity assay was used to determine the inhibitory capacity of recombinant sAPPa. Reduction in relative fluorescence units (RFU) indicates a reduced ability of BACE1 to cleave APP peptides harboring the APP Swedish mutation (n = 3 separate cultures). One-way ANOVA revealed statistically significant differences between group means (F(6, 14)= 7.23, p = 0.001).
Furthermore, Bonferroni-corrected t-test revealed significant differences between control and recombinant sAPPa treatment at the concentrations denoted by *p < 0.0083. Negative control resulted in fluorescence at 4400 RFU (not shown). (c and d) Representative transmitted light micrographs of SHSY5Y cells in a culture treated for 7 days with vehicle (c) or treated sequentially with retinoic acid (RA) for 2 days followed by BDNF for 5 days. Note the robust neurite outgrowth in cells differentiated with RA plus BDNF compared to the control culture. (e) Using a validated fluorescence assay, neurite outgrowth was determined in vehicle-treated control cultures, RA-treated cultures, BDNF-treated cultures, and cultures treated with batimastat plus BDNF. The control value was significantly different than each of the other three values (p < 0.001; n = 25-50 wells in three separate experiments). *p < 0.05, **p < 0.01 as determined by Student's t-test.
hypothesis, SHSY5Y cells were sequentially differentiated with RA followed by BDNF in serum-free media. This sequential process yields a homogenous population of neuronally differentiated cells (Encinas et al. 2000) . These differentiated cells had a visible increase in neurite outgrowth compared to untreated control cultures ( Fig. 4c and d) . RAdifferentiated, BDNF-differentiated, and BDNF-differentiated cells co-treated with batimastat all had significantly more neurite outgrowth compared to control cultures as determined by a validated neurite outgrowth assay (Yeyeodu et al. 2010; Hancock et al. 2015) (Fig. 4e) . Moreover, BDNF treatment resulted in a significant increase in neurite outgrowth compared to cultures treated only with retinoic acid. Cultures co-treated with BDNF and batimastat also exhibited significantly more neurite outgrowth than cultures treated only with retinoic acid. Accordingly, there was no significant difference between BDNF-differentiated cultures and cultures co-treated with BDNF and batimastat (Fig. 4e) . This indicates that there are likely multiple mechanisms by which BDNF promotes neurite outgrowth and enhancement of a-secretase activity is likely only a minor contributor.
Discussion
We found that 3 weeks of voluntary exercise resulted in reduced Ab40 and Ab42 levels in the hippocampus of 2xTgAD mice. This is consistent with previous studies that show that exercise can lead to reductions in soluble Ab levels in other mice models of AD (Adlard et al. 2005; Um et al. 2008) . A recent study indicated that exercise reduces Ab through enhanced clearance (Moore et al. 2016) . However, we found that running wheel exercise results in increased levels of sAPPa in the hippocampus, which was associated with reduced levels of Ab40 and Ab42. This suggests that exercise can serve as a prophylactic by shifting the equilibrium of APP processing away from the amyloidogenic pathway to the non-amyloidogenic pathway. Although it is difficult to determine the mechanism by which exercise exerts this effect, our findings suggest that it involves BDNF, which is a prominent mediator of effects of exercise on hippocampal neuroplasticity (Marosi and Mattson 2014) . Accordingly, we demonstrate that, in SHSY5Y neural cells, BDNF reduces Ab40 and Ab42 levels through its regulation of a-secretase activity. Moreover, BDNF was able to increase secreted sAPPa levels. These results agree well with the notion that exercise can shift the processing of APP to the non-amyloidogenic pathway.
Our findings in cultured neural cells suggest that BDNF promotes redistribution of a-secretase from the cell surface to intracellular compartments where it is catalytically active in processing APP. This finding is consistent with previous studies that show that regulated a-secretase cleavage takes place intracellularly, including in vesicles of the trans-Golgi network (Skovronsky et al. 2000) . The function of intracellular sAPPa is unclear, but our findings corroborate recent evidence which suggests that sAPPa can directly inhibit BACE1 activity (Obregon et al. 2012) , which is predominantly intracellular (Vassar et al. 1999) , active in acidic microenvironments (Hook et al., 2002) , and is rapidly internalized from the cell surface (Huse et al. 2000) .
BDNF has been proposed as a therapeutic in AD primarily because of its ability to promote neuronal survival and neurite outgrowth through its interaction with tropomyosinrelated kinase B (TrkB) receptors and subsequent activation of various signaling pathways including ras, PI-3, extracellular signal-regulated kinase, protein kinase A, and phospholipase Cc/protein kinase C (Patapoutian and Reichardt 2001; Elliott et al. 2005; Lin et al. 2010) . While previous studies have shown that sAPPa can enhance neurite outgrowth (Mattson 1994; Williamson et al. 1996; Small et al. 1999) , our findings in human neuroblastoma cells suggest that BDNF-induced neurite outgrowth occurs primarily through pathways other than sAPPa.
Intensive efforts have been placed on targeting secretases involved in amyloidogenic APP processing (b-and csecretases) for treatment of AD. Several of these efforts have resulted in adverse events and, ultimately, clinical failure (De and Chavez 2015) . Because b-and c-secretase both have multiple substrates other than APP, they may be unattractive targets for prophylaxis. Recent studies indicate that sAPPa participates in a positive feedback loop where it can regulate its own production by directly inhibiting BACE1 (Obregon et al. 2012) . Strategies aimed at promoting this endogenous autoregulatory positive feedback loop may promote the nonamyloidogenic pathway for processing APP and thereby limit off-target adverse events seen with secretase inhibitors. Along with this BACE1 inhibitory capacity, sAPPa has neurotrophic and neuroprotective properties (Mattson et al. 1993) . Indeed, AD patients have lower levels of sAPPa in their cerebrospinal fluid and this correlates with impaired cognition (Almkvist et al. 1997) . Thus, sAPPa holds both prophylactic and therapeutic value.
Uncontrollable psychosocial stress, sleep deprivation, and depression adversely affect cognition and may increase the risk of AD (Rothman and Mattson 2010) . Studies of animal models suggest that chronic elevation of glucocorticoids and suppression of BDNF expression mediate, in part, the adverse effects of uncontrollable stress on hippocampal synaptic plasticity and cognition (Bennett and Lagopoulos 2014) . Moreover, chronic psychosocial stress and sleep deprivation can accelerate the accumulation of Ab in the brains of 3xTgAD mice (Rothman et al. 2012 (Rothman et al. , 2013 . It is not known whether a reduction in BDNF signaling contributes to the amyloidogenic processing of APP caused by chronic stress. Housing mice singly rather than in small groups can be considered a mild isolation stress and might, therefore, be expected to reduce BDNF expression and exacerbate amyloidogenesis. Consistent, with this possibility, it has been reported that environmental enrichment increases hippocampal BDNF expression, reduces Ab accumulation, and improves cognitive performance in AD mouse models (Hu et al. 2010; Stuart et al. 2016) . Moreover, enrichment increases a-secretase activity in the brains of aged dogs (Pop et al. 2010) . In contrast to adverse stressors, there is evidence that running wheel exercise in singly housed mice can protect the brain against a range of stressors including Ab-peptide (Ryan and Kelly 2016) . There is an extensive literature showing that voluntary running wheel exercise enhances hippocampal synaptic plasticity, neurogenesis, and learning and memory in singly housed mice (for review see Voss et al. 2013) . Running wheel exercise stimulates a robust increase in BDNF expression in multiple brain regions, and experimental evidence suggests that BDNF signaling via TrkB mediates many of the beneficial effects of exercise on the brain (Mattson 2012) . Our findings suggest a role for BDNF in promoting exercise-induced a-secretase cleavage of APP to increase the production of neurotrophic sAPPa and reduce production of Ab, which might counteract adverse psychological and age-related stressors.
In order to enhance generation of sAPPa, several studies have sought to identify factors which affect ADAM10, the main enzymatic component of a-secretase (Kuhn et al. 2010) . These studies have found that SIRT1 overexpression (Theendakara et al. 2013) , all-trans retinoic acid, and acitretin (Tippmann et al. 2009 ) can increase expression of ADAM10. We find that BDNF can increase activity of a-secretase without altering ADAM10 levels. Because BDNF may have low blood-brain barrier penetration and has poor biostability (Song et al. 2015) , it is important to identify factors that influence BDNF production in vivo. Exercise, which stimulates BDNF expression in brain cells, is therefore an attractive approach for increasing a-secretase cleavage of APP resulting in reduced generation of Ab and simultaneous production of neuroprotective sAPPa.
